STAT3 in hepatocellular carcinoma: new perspectives
Open accessAbstract
Chronic liver damage and inflammation are strong promoters of hepatocellular carcinoma (HCC) formation. HCC cells communicate with inflammatory and stromal cells via cytokine/chemokine signals. These heterotypic interactions inhibit immunologic anticancer activities and promote protumorigenic activities, such as angiogenesis or invasiveness. STAT3 mediates several reciprocal interactions between liver cancer cells and stromal cells and modulates preconditions of tumor formation such as chronic inflammation. Therefore, activation of STAT3 is considered as a tumor-promoting event in HCC formation. However, the oncogenic role of STAT3 in cancers has been challenged by several reports that suggest a tumor-suppressive activity. Here we discuss tumor-promoting and tumor-suppressive effects of cytokine-activated STAT3 in HCC.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Inhibition of HIF-α hydroxylation can be achieved using PHD inhibitors, including Roxadustat, which is approved in China and Europe for the treatment of renal anemia in CKD, and daprodustat, vadadustat, enarodustat and molidustat, which have been approved in Japan.
“As such, inhibition of HIF-α hydroxylation can be achieved using PHD inhibitors, such as Roxadustat, which is approved in China and Europe for the treatment of renal anemia in CKD, and other PHD inhibitors, daprodustat, vadadustat, enarodustat and molidustat, which have been approved in Japan.637–642”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [639]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 117 · Cited by 63
- Authors
- Svinka, J., Mikulits, W., & Eferl, R.
- Affiliations
- Comprehensive Cancer Center Vienna (AT)
- Venue
- Hepatic Oncology
- Publisher
- Informa UK Limited
- Published
- 2013-12-20
- Volume
- 1
- Issue
- 1
- Pages
- 107-120
- ISSN
- 2045-0923 (ISSN-L)
- 2045-0931
- PMC
- PMC6114013
- OpenAlex
- W2028585237
- Cited by
- 63
- References
- 117
- Citations by year
- 2026: 7 · 2025: 3 · 2024: 3 · 2023: 11 · 2022: 9 · 2021: 10 · 2020: 7 · 2019: 8 · 2017: 1 · 2016: 2 · 2015: 1 · 2014: 1
- FWCI
- 0.14
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Hepatic Oncology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Austrian Science Fund (FWF) DK-plus PhD Program Inflammation and Immunity (P25925-B20)
- Regulation of cholestasis-induced HCC formation (P24802)
- Topics
- Health Sciences › Medicine › Oncology › Cytokine Signaling Pathways and Interactions
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- STAT3, hepatocellular carcinoma, chronic liver inflammation, tumor microenvironment, cytokine signaling, angiogenesis, tumor invasion, tumor suppression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
